Related Experiment Videos
Sialadenitis and systemic reaction associated with phenylbutazone
Australian and New Zealand Journal of Medicine
|June 1, 1982
Summary
Phenylbutazone can cause sialadenitis (salivary gland inflammation), a rare side effect. This study details seven cases, highlighting systemic symptoms like fever and pericarditis, which resolved after drug discontinuation.
Area of Science:
- Pharmacology
- Clinical Medicine
- Toxicology
Background:
- Sialadenitis is an uncommon adverse drug reaction.
- Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID).
Purpose of the Study:
- To report on patients experiencing sialadenitis as a side effect of phenylbutazone.
- To describe the clinical presentation and systemic manifestations associated with phenylbutazone-induced sialadenitis.
Main Methods:
- Retrospective case series.
- Review of patient records from Fairfield Infectious Diseases Hospital over a seven-year period.
Main Results:
- Seven patients were identified with sialadenitis linked to phenylbutazone.
- Common symptoms included salivary gland swelling, fever, rash, conjunctivitis, pleurisy, and hepatic dysfunction.
- Pericarditis was the most severe complication, necessitating corticosteroid treatment in one case.
- Symptoms resolved after phenylbutazone cessation, though recovery took several weeks for some.
Conclusions:
- Sialadenitis is a potential, albeit rare, adverse effect of phenylbutazone.
- Systemic involvement beyond salivary glands is common in these reactions.
- Prompt drug withdrawal is crucial for managing phenylbutazone-induced sialadenitis.